Ivanov K S, Roshchupkin V I, Koshil' O I, Morozov V G, Utkin V N
Antibiot Khimioter. 1994 Jan;39(1):42-6.
Ninety six patients with hemorrhagic fever and the renal syndrome were followed up. Reaferon was included into the complex therapy of 57 cases. The drug was administered intramuscularly in a dose of 2 x 10(6) IU twice a day for 5 days. The use of reaferon in the complex therapy resulted in a decrease in the period of the general intoxication by 3.4 +/- 1.3 days. The use of the drug at the initial stages prevented acute renal failure. When reaferon was used at the stage of oliguria, the level of proteinuria and the risk of the further affection of the kidneys lowered. After the completion of the treatment course with the use of reaferon, a significant increase in the content of the T-helper cells was observed which could be indicative of an activation of the mechanisms providing the immunity development and pathogen elimination. Reaferon promoted a decrease in the concentration of the circulating immune complexes of the blood serum. No significant adverse reactions to the use of reaferon were recorded. The results are in favour of the reaferon use in complex therapy of patients with hemorrhagic fever and the renal syndrome, especially at the initial stages until the syndrome of acute renal failure developed.
对96例出血热伴肾综合征患者进行了随访。57例患者的综合治疗中加入了重组人干扰素α-2b。药物以2×10(6)IU的剂量每日两次肌肉注射，共5天。在综合治疗中使用重组人干扰素α-2b使全身中毒期缩短了3.4±1.3天。在疾病初期使用该药物可预防急性肾衰竭。在少尿期使用重组人干扰素α-2b时，蛋白尿水平及肾脏进一步受累的风险降低。在使用重组人干扰素α-2b完成治疗疗程后，观察到辅助性T细胞含量显著增加，这可能表明参与免疫发育和病原体清除的机制被激活。重组人干扰素α-2b促使血清循环免疫复合物浓度降低。未记录到使用重组人干扰素α-2b的明显不良反应。结果支持在出血热伴肾综合征患者的综合治疗中使用重组人干扰素α-2b，尤其是在急性肾衰竭综合征出现之前的初期阶段。
